Recombinant-Methionyl Human Stem Cell Factor
Hemoglobin SC Disease
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hemoglobin SC Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydroxyurea Nova Laboratories Limited | Phase 2 | BB |
mp4co Sangart | Phase 2 | B |
PREDNISONE TABLETS Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 | CCC |
TACROLIMUS National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | CCC |
Busulphan Tami D. John | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Recombinant-Methionyl Human Stem Cell Factor is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →